Case Solution

Kevin A Schulman, Laura Little, Samyukta Mullangi, Stephen Schleicher
Harvard Business School ()

This case focuses on the impact of a new regulatory pathway, the biosimilars pathway, on the strategy of a large pharmaceutical company that sees its largest product (60% of sales) at risk. In the case, it explores the rationale for the measure, emerging biosimilars market participants, and a number of negative financial outlooks for AbbVie. Given all these risks, has the acquisition created added value for shareholders?

We don‘t have the case solution, but we pay up to $50 for yours!

  • Set a reminder to receive an email after your university‘s case study deadline.
  • Upload your case study solution. We will review it for quality.
  • Get your money via PayPal or to your bank account.